## JCO3 Rec'd PCT/PTO 31 MAR 2005

U.S. DEPARTMENT OF CO.	MMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER									
TRANSMITTAL LETTER	TO THE UNITED STATES	FISHMAN14A									
	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
	NG UNDER 35 U.S.C. 371	10/529650									
CONCERNING A FILI	NG UNDER 35 U.S.C. 3/1	10/529090									
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY CLAIMED									
PCT/IL05/000232	February 24, 2005	February 26, 2004									
TITLE OF INVENTION TREATMENT OF HYPERPROLIFERATIVE DISEASE											
	LIFERATIVE DISEASE										
APPLICANT(S) FOR DO/EO/US											
Pnina FISHMAN et al.											
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
1. [X] This is a FIRST submission of	of items concerning a filing under 35 U.S.C. 3	371.									
2. [] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.											
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)) as soon as the application is in order for											
	ole requirements of 35 U.S.C. 371(c) have be	en complied with.									
4. [ ] The US has been elected (Art 3											
	pplication as filed (35 U.S.C. 371(c)(2))	•									
a. [ ] is attached hereto (required only if not transmitted by the International Bureau).											
b. [X] has been communicated by the International Bureau.											
c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).											
	on of the International Application as filed (3:	5 U.S.C. 371(c)(2)).									
	a. [ ] is attached hereto.										
b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).											
7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))											
a. [] are transmitted herewith (required only if not transmitted by the International Bureau).											
<ul> <li>b. [ ] have been communicated by the International Bureau.</li> <li>c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.</li> </ul>											
d. [X] have not been made ar	_ ·	uniches has 1401 expired.									
		T Article 19 (35 H S.C. 371(c)(3))									
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. [X ] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).											
10. [ ] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36											
(35 U.S.C. 371(c)(5)).											
		e e									
Items 11. to 16. below concern docume											
11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.											
12. [ ] An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.											
13. [X ] A FIRST preliminary amendment.											
14. [X ] An Application Data Sheet under 37 CFR 1.76.											
15. [ ] A substitute specification.											
<ul> <li>16. [ ] A change of power of attorney and/or address letter.</li> <li>17. [ ] A computer-readable sequence form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.</li> </ul>											
17. [ ] A computer-readable sequence form of the sequence fishing in accordance with PC1 Rule 13ter.2 and 37 CFR 1.821-1.825.  18. [ ] A second copy of the published International Application under 35 U.S.C. 154(d)(4).											
19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)											
20. [X ] Other items or information:											
[X ] Courtesy copy of the International Application as filed.											
	<ul><li>[X] Formal drawings, 7 sheets, Figures 1-15.</li><li>[X] Paper copy only of Sequence Listing.</li></ul>										
	[X] The application is (or will be) assigned to: Can-Fite Biopharma Ltd. whose address is 10 Bareket Street, Petach Tikva 4917(										
Israel.											

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) Int		International Application No.		Attorney's Docket No.					
10	152	965	0	PCT/IL05/000232			FISHMAN14A		
10/529650 PCT/IL05/000232 21. The following fees are submitted:						CALCULATIONS PTO USE ONLY			
[xx] a) BASIC NATIONAL FEE (37 CFR 1.492(a))\$300.00									
[xx ] b) SEARCH FEE (37 CFR 1.492(b))									
[ ] US was International Searching Authority\$100.00									
[ ] Other ISR provided to USPTO\$400.00									
[x ] All other situations\$500.00						\$ 1,000.00			
[xx ] c) EXAMINATION FEE (37 CFR 1.492 (c))									
[ ] IPEA/US gave wholly favorable IPER\$100.00									
[x ] All other situations\$200.00						\$200.00			
TOTAL OF ABOVE CALCULATIONS :						ATIONS:			
Surcharge of \$130.0 months from the ea				ration later than [ ] 20 [	] 30		\$		
TOTAL SHEETS				of each additional 50 or fra	ction	RATE			
35- 100		/50	thereof (re	ound up to a whole numbe	r)	(1.492(g)) X \$250.00		<u> </u>	
CLAIMS	l	Numbe	r Filed	Number Extra	Rate (	.492 (d-f))			
Total Claims		20- 2		T. Sinov. Data	X \$ 50	` "	\$	<del>                                     </del>	
Independent Claims	5	4-	3 =	1	X \$200	0.00	\$200.00		
Multiple Dependen	t Claims (	if applicable)			+ \$36	0.00	\$		
				TOTAL OF ABOVE			\$1,200.00		
Reduction of ½ for CFR 1.27.	filing by s	mall entity, i	f applicable	e. Applicant claims small	entity sta	itus. See 37	\$600.00		
0111.27.					SU	JBTOTAL =	\$600.00	†	
				ranslation later than [ ]	20 [ ]:	30	\$		
months from the earliest claimed priority date (37 CFR 1.492(i)).  TOTAL NATIONAL FEE =						\$600.00	<u> </u>		
Fee for recording th	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be						\$	<del> </del>	
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +									
TOTAL FEES ENCLOSED =						\$600.00			
							Amount to be: refunded	\$	
							charged	\$	
Payment Method	d (check	one only)							
a. [] A check i	n the amo	ount of \$		to cover the above	fees is e	nclosed.			
a. [ ] A check in the amount of \$ to cover the above fees is enclosed.  b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$600.00, is attached.									
2. [21] Steam Said Layment Form (1.10-2030), additing payment in the amount of 9000.00, is attached.									
c. [ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ to cover the above fees.  A duplicate copy of this sheet is enclosed.									
Handling of Fee Deficiencies (check one only)									
[X ] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.									
[ ] If a deficiency exists in the basic national fee set by 37 CFR 1.492(a), please charge it to Deposit Account 02-4035. At this time, no authorization is given to charge any other fees.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
Direct all correspondence to the address associated with								Smol	
CUSTOMER NUMBER 001444, which is currently:						SIGNATURE	/		
						Roger L. Browdy			
624 NINTH STREET, N.W., SUITE 300						NAME			
WASHINGTON, D.C. 20001							25,618		
TEL: (202) 628-	5197						REGISTRATION NUMBE	R	
FAX: (202) 737-3528  Data of this submission. March 21, 2005									
Date of this submission: March 31, 2005							RLB:ccw		